After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
As a crucial test of the cytokine approach nears from Nektar, encouraging early data from Lilly and Roche confirm that the competition is hotting up.
Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.